Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Adults, Elderly and Specified Risk Groups
2008-000558-11Phase 3Completed
- Sponsor
- Baxter International Inc.
- Start
- Apr 2008
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of inactivated Vero cell based whole virus influenza A/H5N1 in Influenza A infection (3 arms), sponsored by Baxter International Inc. Primary endpoints: Safety and tolerability and Persistence of H5N1 influenza antibodies. Started Apr 2008; status: completed.
02
Drugs
inactivated Vero cell based whole virus influenza A/H5N1
03
Conditions
Influenza A infection
Beyond the preview
Go deeper on 2008-000558-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000558-11.